A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This study evaluates the clinical benefit of TAS-102 in participants with metastatic
urothelial carcinoma who are resistant to cisplatin or carboplatin front-line and checkpoint
inhibitors as second line therapy. All participants will receive TAS-102 in oral form twice
per day on Days 1-5 and Days 8-12 of each 28 day cycle.